These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 4849495)

  • 21. Comparative absorption and pharmacokinetic studies on proxyphylline in ordinary and slow release tablets.
    Graffner C; Johnsson G; Sjögren J
    Acta Pharm Suec; 1974 May; 11(2):125-32. PubMed ID: 4417816
    [No Abstract]   [Full Text] [Related]  

  • 22. High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation.
    Nabais T; Brouillet F; Kyriacos S; Mroueh M; Amores da Silva P; Bataille B; Chebli C; Cartilier L
    Eur J Pharm Biopharm; 2007 Mar; 65(3):371-8. PubMed ID: 17275270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Injection molding technic for the production of oral retard preparations. 2. Structure of the matrix].
    Hüttenrauch R; Schmeiss U
    Pharmazie; 1975 Apr; 30(4):229-33. PubMed ID: 1153488
    [No Abstract]   [Full Text] [Related]  

  • 24. [Types of controlled-release dosage forms].
    Huang SY
    Yao Xue Xue Bao; 1986 Feb; 21(2):152-7. PubMed ID: 3529817
    [No Abstract]   [Full Text] [Related]  

  • 25. Dissolution testing of oral modified-release dosage forms.
    Garbacz G; Klein S
    J Pharm Pharmacol; 2012 Jul; 64(7):944-68. PubMed ID: 22686342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Galenical possibilities and problems in protraction of drug effects (author's transl)].
    Müller F
    Arzneimittelforschung; 1976; 26(1A):115-21. PubMed ID: 7277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Peroral drugs with delayed action. VI. Effect of stearic acid and its glycerin esters on the retarded release of drugs].
    Starha L; Chalabala M
    Cesk Farm; 1971 Mar; 20(2):60-2. PubMed ID: 5550004
    [No Abstract]   [Full Text] [Related]  

  • 28. Dry elixir formulations of dexibuprofen for controlled release and enhanced oral bioavailability.
    Kim SR; Kim JK; Park JS; Kim CK
    Int J Pharm; 2011 Feb; 404(1-2):301-7. PubMed ID: 21093566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biological availability].
    Weber E; Gundert-Remy U
    Arzneimittelforschung; 1975 Jul; 25(7a):1158-62. PubMed ID: 1242346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Theoretical analysis of release kinetics of coated tablets containing constant and non-constant drug reservoirs.
    Zhou Y; Chu JS; Li JX; Wu XY
    Int J Pharm; 2010 Jan; 385(1-2):98-103. PubMed ID: 19879936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biopharmacy--does it concern clinical medicine? Peroral depot preparations].
    Nielsen GH; Skinhøj A
    Ugeskr Laeger; 1984 Mar; 146(12):896-9. PubMed ID: 6719594
    [No Abstract]   [Full Text] [Related]  

  • 32. Strategies to improve oral drug bioavailability.
    Gomez-Orellana I
    Expert Opin Drug Deliv; 2005 May; 2(3):419-33. PubMed ID: 16296764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
    Möller H; Wirbitzki E
    Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective in-vivo utilization of lipid-based nanoparticles as drug carrier for carvedilol phosphate.
    Chakraborty S; Shukla D; Vuddanda PR; Mishra B; Singh S
    J Pharm Pharmacol; 2011 Jun; 63(6):774-9. PubMed ID: 21585374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The utility of cyclodextrins for enhancing oral bioavailability.
    Carrier RL; Miller LA; Ahmed I
    J Control Release; 2007 Nov; 123(2):78-99. PubMed ID: 17888540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Injection method for delivery of long-acting narcotic antagonists.
    Leafe TD; Sarner SF; Woodland JH; Yolles S; Blake DA; Meyer FJ
    Adv Biochem Psychopharmacol; 1973; 8(0):569-75. PubMed ID: 4794963
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro methods to assess drug precipitation.
    Dai WG
    Int J Pharm; 2010 Jun; 393(1-2):1-16. PubMed ID: 20347943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IVIVC of controlled release formulations: physiological-dynamical reasons for their failure.
    Dokoumetzidis A; Macheras P
    J Control Release; 2008 Jul; 129(2):76-8. PubMed ID: 18538435
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of process parameters and equipment on dry foam formulation properties using indomethacin as model drug.
    Sprunk A; Page S; Kleinebudde P
    Int J Pharm; 2013 Oct; 455(1-2):189-96. PubMed ID: 23891743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system.
    Dokoumetzidis A; Macheras P
    Int J Pharm; 2006 Sep; 321(1-2):1-11. PubMed ID: 16920290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.